{
 "ticker": "BBH",
 "name": "VanEck Biotech ETF",
 "issuer": "VanEck",
 "desk": "themes",
 "url": "https://etfiq.com/funds/BBH",
 "html": "https://etfiq.com/funds/BBH",
 "markdown": "https://etfiq.com/funds/BBH.md",
 "as_of": "2026-09-11",
 "verdict": "BBH holds 24 stocks, and 39% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "60.7%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBH, already in the S&P 500: 60.7%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBH, active share vs the S&P 500: 99.0%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "72.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBH, top ten holdings: 72.0%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+36.1%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBH, total return, 1 year: +36.1%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$396m",
   "source": "SEC filing, whole fund, as filed for Jun 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "BBH, net assets: $396m (SEC filing, whole fund, as filed for Jun 30, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.35%",
   "source": "485BPOS XBRL, Jan 27, 2026",
   "as_of": "2026-09-11",
   "sentence": "BBH, expense ratio: 0.35% (485BPOS XBRL, Jan 27, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Jan 4, 2010",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "60.7%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.0%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "48.4%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "97.4%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "72.0%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "24",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Sep 10, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "Amgen Inc 14.3%, Gilead Sciences Inc 13.0%, Vertex Pharmaceuticals Inc 8.4%, Regeneron Pharmaceuticals Inc 7.0%, Moderna Inc 5.8%, Natera Inc 5.2%, Iqvia Holdings Inc 5.1%, Revolution Medicines Inc 5.1%, Argenx Se 4.7%, Illumina Inc 3.2%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$396m",
   "source": "SEC filing, whole fund, as filed for Jun 30, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22126.0%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.35%",
   "source": "485BPOS XBRL, Jan 27, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.35%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "IBBQ 53%, FBT 44%, PBE 43%, BMED 35%, HELX 25%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+22.3%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+19.0 pts",
   "Gap to Nasdaq-100": "+23.1 pts"
  },
  {
   "window": "6 months",
   "Total return": "+22.9%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+6.9 pts",
   "Gap to Nasdaq-100": "+2.2 pts"
  },
  {
   "window": "1 year",
   "Total return": "+36.1%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+18.6 pts",
   "Gap to Nasdaq-100": "+13.1 pts"
  },
  {
   "window": "3 years",
   "Total return": "+44.8%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u221233.1 pts",
   "Gap to Nasdaq-100": "\u221250.3 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+715.8%",
   "S&P 500": "+804.4%",
   "Gap to S&P 500": "\u221288.5 pts",
   "Gap to Nasdaq-100": "\u2212958.1 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of BBH is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 10, 2026, 61% of BBH by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different."
  },
  {
   "q": "What does BBH hold?",
   "a": "24 positions as published by its issuer for Sep 10, 2026, with the top ten at 72% of the fund. The largest are Amgen Inc at 14.3%, Gilead Sciences Inc at 13.0%, Vertex Pharmaceuticals Inc at 8.4%."
  },
  {
   "q": "Has BBH beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 BBH returned +36.1% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 18.6 points."
  },
  {
   "q": "What does BBH cost?",
   "a": "The prospectus expense ratio is 0.35% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.35%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}